2026-01-27 - Analysis Report
**Company Overview:**
Align Technology is a medical device company that specializes in creating clear aligner therapy for teeth straightening.

**Return Rate Comparison:**
- Cumulative return of review stock (ALGN): -16.37%
- Cumulative return of comparison stock (S&P 500, VOO): 127.58%
- Divergence (max: 241.70, min: -162.90, current: -142.20, relative divergence: 5.10%)

The comparison stock (S&P 500, VOO) has a higher cumulative return rate, and the review stock (ALGN) has a negative cumulative return rate, which indicates a significant divergence between the two stocks.

**Alpha, Beta Analysis:**
| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 65.0% | 48.7% | 57.0% | 1.5 | 15.2B |
| 2017-2019  | 79.0% | 51.1% | 54.0% | 1.6 | 20.2B |
| 2018-2020  | 81.0% | 56.9% | 58.0% | 1.5 | 38.7B |
| 2019-2021  | 166.0% | 53.3% | 101.0% | 1.5 | 47.6B |
| 2020-2022  | -70.0% | 73.3% | -74.0% | 1.5 | 15.3B |
| 2021-2023  | -195.0% | 73.3% | -213.0% | 1.7 | 19.9B |
| 2022-2024  | -169.0% | 65.1% | -198.0% | 1.7 | 15.1B |
| 2023-2025  | -62.0% | 60.0% | -138.0% | 1.5 | 11.3B |

The review stock (ALGN) has a wide range of returns across different periods. The CAGR, MDD, Alpha, and Beta values vary significantly across each period, indicating volatility in the stock's performance.

**Stock Price Fluctuations:**
- 5-day SMA: $168.16
- 20-day SMA: $165.98
- 60-day SMA: $153.75
- Close: $167.65
- Last-market: $167.65 (previous close: $168.73, change: -0.64)

The stock price has been trending downwards, as indicated by the lower closing price and negative change. The short-term moving averages (5-day and 20-day SMA) are above the closing price, suggesting a potential sell signal.

**RSI, PPO, Delta_Previous_Relative_Divergence, Expected_Return:**
- Market Risk Indicator (MRI): 0.70 (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
- RSI: 61.46
- PPO: -0.42
- Recent (20 days) relative divergence change: -0.10 (-): worsening
- 7-day Rank change: 9 (+): rank up
- 7-day Dynamic Expected Return change: 798.50 (+): improving
- Expected Return (%): -858.40%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

The review stock (ALGN) has a market risk indicator of 0.70, which indicates a medium investment risk. The RSI and PPO values are lower than average, suggesting a sell signal. The recent relative divergence change is worsening, and the 7-day rank change is improving, but the expected return is extremely low (-858.40%).

**Recent News & Significant Events:**
- 2026-01-26: How Investors Are Reacting To Align Technology (ALGN) Margin Roadmap and New 0x3 Treatment Suite - simplywall.st
- 2026-01-22: Assessing Align Technology (ALGN) Valuation After Recent Share Price Momentum And Mixed Signals - Yahoo Finance
- 2026-01-23: Piper Sandler reiterates Overweight rating on Align Technology stock - Investing.com
- 2026-01-19: Align Technology Q4 Preview: Even After A Big Drop In Price, Itâ€™s Too Expensive (ALGN) - Seeking Alpha
- 2025-10-30: ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash - Zacks Investment Research
- 2025-10-30: Why Align Technology Stock Popped Today - The Motley Fool

The recent news and events suggest mixed signals from analysts and investors, with some indicating a potential buy opportunity and others warning of high investment risk.

**Analyst Opinions:**
- Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.17 (~Buy)
- Opinions: 15
- Target Price (avg/high/low): 183.87 / 220.00 / 150.00

The analyst consensus is to buy the stock, with a target price range of $150.00 to $220.00.

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 0.78 | 1.00 B$ |
| 2025-08-06 | 1.72 | 1.01 B$ |
| 2025-05-08 | 1.27 | 0.98 B$ |
| 2024-11-05 | 1.55 | 0.98 B$ |
| 2025-11-05 | 1.55 | 0.98 B$ |

The review stock (ALGN) has reported mixed earnings with varying EPS and revenue numbers across different periods.

**Financial Information - 5. Financial Information: Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.00B | 64.20% |
| 2025-06-30 | $1.01B | 69.94% |
| 2025-03-31 | $0.98B | 69.45% |
| 2024-12-31 | $1.00B | 70.03% |
| 2024-09-30 | $0.98B | 69.72% |

The review stock (ALGN) has reported increasing revenue across different periods, with a slight decrease in profit margin in Q3 2025.

**Financial Information - 5. Financial Information: Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $3.96B | 1.43% |
| 2025-06-30 | $3.91B | 3.18% |
| 2025-03-31 | $3.79B | 2.46% |
| 2024-12-31 | $3.85B | 2.69% |
| 2024-09-30 | $3.94B | 2.94% |

The review stock (ALGN) has reported increasing equity across different periods, with a slight decrease in ROE in Q2 2025.

**Comprehensive Analysis (Summary of previous items):**
The review stock (ALGN) has reported mixed results, with a significant divergence from the comparison stock (S&P 500, VOO). The stock price has been trending downwards, with a sell signal indicated by the RSI and PPO values. The analyst consensus is to buy the stock, but the expected return is extremely low. The recent news and events suggest mixed signals from analysts and investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.